**REFEREERBIJEENKOMST UNIT TRANSFUSIEGENEESKUNDE**

**Datum**

donderdag 2 september 2021, 12.00 – 13.00 uur

**Titel**

Immunotherapie 2.0 voor auto-immuun aandoeningen: de neonatale Fc receptor

**Te bespreken artikelen**

* Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia, <https://pubmed.ncbi.nlm.nih.gov/32886753/>
* Phase 2 of efgartigimod, a novel FcRN antagonist, in adults patiens with primary immune thrombocytopenia, <https://pubmed.ncbi.nlm.nih.gov/31821591/>
* Targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases and maternal-fetal immune cytopenias, <https://doi.org/10.1111/trf.16341>

**Voortrekker**

Jean-Louis Kerkhoffs, transfusiespecialist Unit Transfusiegeneeskunde en internist-hematoloog HAGA Ziekenhuis

**Locatie**

via MS-teams

Microsoft Teams meeting

**Join on your computer or mobile app**

[Click here to join the meeting](https://teams.microsoft.com/l/meetup-join/19%3ameeting_NmEwMTU5ODAtMDZkMy00OGQxLTk4ZjEtMGQ4OWM0YTA0ZTNk%40thread.v2/0?context=%7b%22Tid%22%3a%22e4624e46-dc3b-4fd0-a815-fe720d1de0dd%22%2c%22Oid%22%3a%22b95580c9-75a2-411e-b4c3-6ccbdf62dd0d%22%7d)